Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Payne, Daniel C.; Iblan, Ibrahim; Rha, Brian; Alqasrawi, Sultan; Haddadin, Aktham; Nsour, Mohannad Al; Alsanouri, Tarek; Ali, Sami Sheikh; Harcourt, Jennifer L.; Miao, Congrong; Tamin, Azaibi; Gerber, Susan I.; Haynes, Lia M.; Abdallat, Mohammad

doi:10.3201/eid2210.160706

Cited by 208 publications

(201 citation statements)

References 10 publications

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…Since the first reported case of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 (Zaki et al, 2012), small and large outbreaks have occurred, resulting in 1917 MERS-CoV infections and 677 related deaths to date (WHO, 2017). To understand this fatal respiratory viral infection, several serologic investigations have been conducted (Corman et al, 2016;Min et al, 2016;Park et al, 2015;Payne et al, 2016). However, practical analysis of serodiagnostic parameters for clinical usage was limited in previous studies, due to insufficient sample size or clinical information.…”

Section: Introductionmentioning

confidence: 99%

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Müller

Seok

et al. 2017

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).

show abstract

Section: Introductionmentioning

confidence: 99%

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Müller

Seok

et al. 2017

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

show abstract

“…Hence, taking into account the waning of virus-specific humoral responses, generating a long-lived memory T cell response through vaccination could be favorable, but as proper B-and T-cell immune responses are required for efficient protection, vaccination should target the induction of both. At the moment we lack information concerning the longevity of anamnestic immune responses following MERS-CoV infection, except for a recent study showing that antibody responses, albeit reduced, persisted up to 34 months post-infection [33]. The role of immune responses in protection is also in line with the observed increased fatality among the aged population following MERS-CoV infection.…”

Section: Immune Correlates Of Protectionmentioning

confidence: 92%

Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches

Okba

Raj

Haagmans

2017

Current Opinion in Virology

View full text Add to dashboard Cite

Middle East respiratory syndrome coronavirus (MERS-CoV) is a cause of severe respiratory infection in humans, specifically the elderly and people with comorbidities. The re-emergence of lethal coronaviruses calls for international collaboration to produce coronavirus vaccines, which are still lacking to date. Ongoing efforts to develop MERS-CoV vaccines should consider the different target populations (dromedary camels and humans) and the correlates of protection. Extending on our current knowledge of MERS, vaccination of dromedary camels to induce mucosal immunity could be a promising approach to diminish MERS-CoV transmission to humans. In addition, it is equally important to develop vaccines for humans that induce broader reactivity against various coronaviruses to be prepared for a potential next CoV outbreak.

show abstract

“…118 MERS-CoV antibodies, including neutralizing antibodies, were detectable in 6 (86%) of 7 persons serologically positive or indeterminate for at least 34 months after the nosocomial outbreak in Jordan in 2012. 119 Autopsy of a 45 year-old man who died of MERS-CoV infection in Abu Dhabi in 2014 revealed DAD. Pneumocytes and epithelial syncytial cells were important targets of MERS-CoV Ag, because DPP4 receptors were found in scattered pneumocytes and syncytial cells but no evidence of extrapulmonary MERS-CoV Ags were detected, including the kidneys.…”

Section: Pathogenesismentioning

confidence: 99%

Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome)

Hui

2017

Clinics in Chest Medicine

128

137

View full text Add to dashboard Cite

Bats are the natural reservoirs of severe acute respiratory syndrome (SARS)-like coronaviruses (CoVs) and likely the reservoir of Middle East respiratory syndrome (MERS)-CoV. The clinical features of SARS-CoV infection and MERS-CoV infection are similar but MERS-CoV infection progresses to respiratory failure more rapidly. Although the estimated pandemic potential of MERS-CoV is lower than that of SARS-CoV, the case fatality rate of MERS is higher. The transmission route and the possibility of other intermediary animal sources remain uncertain among many sporadic primary cases. Clinical trial options for MERS-CoV infection include monotherapy and combination therapy.

show abstract

Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Cited by 208 publications

References 10 publications

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches

Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome)

Contact Info

Product

Resources

About